Scientists develop new treatment for non-alcoholic fatty liver!

Medicines Network, August 20, published in the international journal The Lancet Gastroenterology and Hepatology, scientists from the Medical University of Vienna, Austria, explained the synthetic bile acid combined active agent non-bear deoxycholic acid (nor-urso) in the treatment of primary sclerosing bile ductitis (PSC), primary sclerosing biliary disease is a disease that has not been cured to datein a clinical trial, researchers found that nor-urso is also effective in treating non-alcoholic fatty liver disease, which is currently affected by non-alcoholic fatty liver, which is often caused by poor lifestyle, excessive fat and sugar in the body, and lack ofexercise, often in parallel with obesityIn the 50-60 year old population, 35%-50% of the population will develop fatty liver, fatty liver is a silentdisease, usually only in the individual accidental physical examination, but the long-term fatty liver will seriously affect the body'shealth, and lead to cirrhosis and liver cancer, in all fatty liver disease, about 10%-30% of the most dangerous fatty liver hepatitis / NASH, and then 15%-25% of patients with the most dangerous fatty liver cirrhoriosic liver cirrhosis, which subsequently causes 15-25% of patients with hepatic hepatic hepatitis/NASH, which subsequently causes the most dangerous hepatotic hepatitis/NASH, which subsequently causes 15-25% of patients with fatty liver cirrhotsresearchers point out that we recently completed phase IIa clinical trials of the nor-urso study with the help of researchers from several Australian and German research centers, which showed positive therapeutic effects when used to treat non-alcoholic fatty liver diseaseAnd synthetic bile acids can also protect the liver from inflammation, thus avoiding the occurrence of fibrosis, the researchers used the hormonal effects of bile acid as a targetTrauner says bile acid, like steroid hormones, circulates in the body and regulates the body's various metabolic processes, and in fatty liver disease, if the patient develops bile acid signal resistance, the body's normal metabolic process may not be able to perform proper functions, and nor-urso can re-enhance the hormone effects of bile acid, which may help improve the patient's prognosis and quality of lifeNow researchers want to further investigate whether nor-urso can effectively suppress the most common cause of death in patients with fatty liver disease, such as cardiovascular disease, such ascardiacor stroke, to improve life expectancy, which the researchers say seems logical, which we are optimistic about, but has not yet confirmedin addition to, the researchers developed two other potential therapies using bile acid, one of which can target the activation of the bile acid receptor FXR (bile acid sensor), which is mainly involved in the metabolic processes of several organisms, such as the regulation of lipid and glucose metabolism, as well as bile acid and synthesis and circulation This year, researchers will publish Phase III clinical trials using obetic holic acid as the treatment of primary bile ductitis (PBC), the first clinically available FXR ligand, which is expected to be used as a second-line therapy for PBC in the near future, and can also bring health benefits to patients with fatty liver/NASH in addition to Obercacid, there are currently other new FXR activators or ligands available, which do not carry bile acid structure (so-called nonsteroidal FXR ligands) and have good tolerance; Based on the spirit of individualized therapy, using the signaling characteristics and hormonal effects of bile acid, these promising options may provide patients with the possibility of personalized treatment, and in the future we will combine these to help treat patients and improve their quality of life, said The researcher, Trauner references: 1 Stefan Trausssnigg et al Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty far liver disease: a double-blind, randomised, placebo-controlled, 2 phase-find-trial, Lancet Gastroology (2019) DOI: 10.1016/S2468-1253 (19) 30184-0
2 Michael Trauner et al Long-term effic and safety of obeticicic for patients withthe-primary-beribilichorana DOI: 10.1016/S2468-1253 (19) 30094-9
3 Nonsteroidal Farnesoid EIEEEEIAgonist Cilofexor (GS-9674) Markers of Cholestasis and Liver Injury Insins Primary, 2019 DOI: 10.1002/hep.30509 4 New treatment option for non-fattyalcoholicdisease disease medical university of Vienna